免疫治疗时代下的肝癌肝移植

李照; 朱继业

doi:10.3969/j.issn.1001-5256.2021.02.001

免疫治疗时代下的肝癌肝移植

DOI: 10.3969/j.issn.1001-5256.2021.02.001

李照,
朱继业^,

北京大学人民医院肝胆外科，北京大学器官移植研究所，北京 100044

作者贡献声明：李照负责撰写文章；朱继业负责指导并最终定稿。

详细信息

作者简介:
李照(1982—)，男，主任医师，副教授，医学博士，主要从事肝胆胰外科临床和基础研究

通信作者:
朱继业，gandanwk@vip.sina.com

中图分类号: R735.7;R617
计量
- 文章访问数: 606
- HTML全文浏览量: 339
- PDF下载量: 129
- 被引次数: 0
出版历程
- 收稿日期: 2020-10-09
- 录用日期: 2020-10-09
- 出版日期: 2021-02-20

Liver transplantation for liver cancer in the era of immunotherapy

Zhao LI,
Jiye ZHU^,

Department of Hepatobilliary Surgery, Peking University People's Hospital, Peking University Institute of Organ Transplantation, Beijing 100044, China

摘要

摘要:
我国大部分肝癌患者在就诊时不能获得根治性手术治疗，近年来肝癌免疫治疗的突破性进展为这些中晚期肝癌患者带来了曙光。在肝癌肝移植领域，免疫治疗更是因为在肿瘤免疫和移植免疫中扮演的双重角色而备受关注。在术前降期治疗和移植术后肿瘤复发的治疗中均有创新性的应用。在免疫治疗的时代下如何应用移植肿瘤学思维使肝癌肝移植患者获益是一个崭新的课题，这需要在临床实践中进行多学科团队协作，探讨最佳的肝癌肝移植患者治疗策略，最终改善中晚期肝癌患者的预后。
- 肝肿瘤 /
- 肝移植 /
- 免疫疗法
Abstract:
Most patients with liver cancer in China cannot get radical surgical treatment at the time of diagnosis, and the breakthrough of immunotherapy for liver cancer in recent years has brought new hope to the patients with advanced liver cancer. In the field of liver transplantation for liver cancer, immunotherapy has attracted much attention because of its dual role in tumor immunity and transplantation immunity. There are also innovative applications of immunotherapy in preoperative down-staging treatment and the treatment of tumor recurrence after transplantation. In the era of immunotherapy, how to apply the thinking of transplant oncology to benefit liver cancer patients undergoing liver transplantation is a brand-new topic, and this requires multidisciplinary collaboration in clinical practice to explore the best treatment strategies for liver cancer patients undergoing liver transplantation and finally improve the prognosis of patients with advanced liver cancer.
- Liver Neoplasms /
- Liver Transplantation /
- Immunotherapy

HTML全文

参考文献(17)

[1]	FINN RS, QIN S, IKEDA M, et al. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905. DOI: 10.1056/NEJMoa1915745
[2]	HATO T, GOYAL L, GRETEN TF, et al. Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions[J]. Hepatology, 2014, 60(5): 1776-1782. DOI: 10.1002/hep.27246
[3]	DISIS ML. Mechanism of action of immunotherapy[J]. Semin Oncol, 2014, 41(Suppl 5): s3-s13.
[4]	DATTA M, COUSSENS LM, NISHIKAWA H, et al. Reprogramming the tumor microenvironment to improve immunotherapy: Emerging strategies and combination therapies[J]. Am Soc Clin Oncol Educ Book, 2019, 39: 165-174.
[5]	EL-KHOUEIRY AB, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502. DOI: 10.1016/S0140-6736(17)31046-2
[6]	QIN S, REN Z, MENG Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: A multicentre, open-label, parallel-group, randomised, phase 2 trial[J]. Lancet Oncol, 2020, 21(4): 571-580. DOI: 10.1016/S1470-2045(20)30011-5
[7]	KUDO M. Immune checkpoint inhibition in hepatocellular carcinoma: Basics and ongoing clinical trials[J]. Oncology, 2017, 92(Suppl 1): 50-62.
[8]	IKEDA M, SUNG MW, KUDO M, et al. A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC)[J]. J Clin Oncol, 2018, 36(15 Suppl): 4076.
[9]	KASEB AO, VENCE L, BLANDO J, et al. Immunologic correlates of pathologic complete response to preoperative immunotherapy in hepatocellular carcinoma[J]. Cancer Immunol Res, 2019, 7(9): 1390-1395. DOI: 10.1158/2326-6066.CIR-18-0605
[10]	CHEN X, ZHANG Y, ZHANG N, et al. Lenvatinib combined nivolumab injection followed by extended right hepatectomy is a feasible treatment for patients with massive hepatocellular carcinoma: A case report[J]. Onco Targets Ther, 2019, 12: 7355-7359. DOI: 10.2147/OTT.S217123
[11]	WEHRENBERG-KLEE E, GOYAL L, DUGAN M, et al. Y-90 radioembolization combined with a PD-1 inhibitor for advanced hepatocellular carcinoma[J]. Cardiovasc Intervent Radiol, 2018, 41(11): 1799-1802. DOI: 10.1007/s00270-018-1993-1
[12]	SCHWACHA-EIPPER B, MINCIUNA I, BANZ V, et al. Immunotherapy as a downstaging therapy for liver transplantation[J]. Hepatology, 2020. [Epub ahead of print]
[13]	SABERIANFAR S, NGUYEN LS, MANOUCHEHRI A, et al. Solid organ transplant rejection associated with immune-checkpoint inhibitors[J]. Ann Oncol, 2020, 31(4): 543-544. DOI: 10.1016/j.annonc.2020.01.012
[14]	HO CM, CHEN HL, HU RH, et al. Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: A review from a transplant oncology perspective[J]. Ther Adv Med Oncol, 2019, 11: 1758835919843463.
[15]	de TONI EN, GERBES AL. Tapering of immunosuppression and sustained treatment with nivolumab in a liver transplant recipient[J]. Gastroenterology, 2017, 152(6): 1631-1633. DOI: 10.1053/j.gastro.2017.01.063
[16]	RAMMOHAN A, REDDY MS, FAROUK M, et al. Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: The silver bullet?[J]. Hepatology, 2018, 67(3): 1166-1168. DOI: 10.1002/hep.29575
[17]	MUNKER S, de TONI EN. Use of checkpoint inhibitors in liver transplant recipients[J]. United European Gastroenterol J, 2018, 6(7): 970-973. DOI: 10.1177/2050640618774631